Lukole Eliud Andrea, Cook Jackie, Mosha Jacklin F, Matowo Nancy S, Kulkarni Manisha A, Mallya Elizabeth, Aziz Tatu, Martin Jacklin, Rowland Mark, Kleinschmidt Immo, Manjurano Alphaxard, Mosha Franklin W, Protopopoff Natacha
Department of Parasitology, Mwanza Medical Research Centre, National Institute for Medical Research, Mwanza, Tanzania.
Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK.
BMC Public Health. 2025 Jan 28;25(1):346. doi: 10.1186/s12889-025-21586-x.
Long-lasting insecticidal nets (LLINs) were once fully effective for the prevention of malaria; however, mosquitoes have developed resistance to pyrethroids, the main class of insecticides used on nets. Dual active ingredient LLINs (dual-AI LLINs) have been rolled out as an alternative to pyrethroid (PY)-only LLINs to counteract this. Understanding the minimum community usage at which these LLINs elicit an effect that also benefits non-users against malaria infection is important.
We conducted a secondary analysis of a 3-year randomized controlled trial (RCT) in 84 clusters in North-western Tanzania to evaluate the effectiveness of three dual-AI LLINs: pyriproxyfen and alpha(α)-cypermethrin, chlorfenapyr and α-cypermethrin, and the piperonyl-butoxide (PBO) and permethrin compared to α-cypermethrin only LLINs. We measured malaria infection prevalence using 5 cross-sectional surveys between 2020 and 2022. We assessed net usage at the cluster level and malaria infection in children aged from 6 months to 14 years in 45 households per cluster. The trial was registered as a clinical trial on www.
gov : ClinicalTrials.gov (NCT03554616) on 2018-06-13.
A total of 22,479 children from 12,654 households were tested for malaria using rapid diagnostic tests in January 2020, 2021, & 2022 and July 2020 & 2021. Among non-users, community-level usage of > 40% of dual-AI LLIN was significantly associated with protection against malaria infection: chlorfenapyr arm (OR: 0.44 (95% CI: 0.27-0.71), p = 0.0009), PBO arm (OR: 0.55 (95% CI: 0.33-0.94), p = 0.0277) and pyriproxyfen arm (OR: 0.61 (95% CI: 0.37-0.99), p = 0.0470) compared with non-users in clusters with > 40% usage of pyrethroid-only LLINs. There were indications of some protection against malaria infection to non-users in the chlorfenapyr arm when community-level usage was ≤ 40% (OR: 0.65 (95% CI: 0.42-1.01), p = 0.0528) compared to those living in clusters with > 40% usage of pyrethroid-only LLINs.
Our study demonstrated that at a community usage of 40% or more of dual-AI LLINs non-users benefited from the presence of these nets. Noticeably, even when usage was ≤ 40% in the chlorfenapyr arm, non-users were better protected than non-users in the higher coverage pyrethroid-only arm. The greater difference in malaria risk observed between users and non-users indicates that LLINs play a crucial role in providing personal protection against malaria infection for the people using the net.
长效驱虫蚊帐(LLINs)曾对预防疟疾完全有效;然而,蚊子已对拟除虫菊酯产生抗性,拟除虫菊酯是蚊帐上使用的主要杀虫剂类别。双活性成分长效驱虫蚊帐(双AI长效驱虫蚊帐)已作为仅含拟除虫菊酯(PY)的长效驱虫蚊帐的替代品推出,以应对这一情况。了解这些长效驱虫蚊帐在何种最低社区使用率下能产生使非使用者也受益于预防疟疾感染的效果很重要。
我们对坦桑尼亚西北部84个群组进行的一项为期3年的随机对照试验(RCT)进行了二次分析,以评估三种双AI长效驱虫蚊帐的有效性:吡丙醚和α-氯氰菊酯、虫螨腈和α-氯氰菊酯,以及增效醚(PBO)和氯菊酯,并与仅含α-氯氰菊酯的长效驱虫蚊帐进行比较。我们在2020年至2022年期间使用5次横断面调查来测量疟疾感染率。我们评估了群组层面的蚊帐使用率以及每个群组中45户6个月至14岁儿童的疟疾感染情况。该试验于2018年6月13日在www.CLINICALTRIALS.gov上注册为临床试验:ClinicalTrials.gov(NCT03554616)。
在2020年1月、2021年、2022年以及2020年7月和2021年,共对来自12,654户家庭的22,479名儿童进行了疟疾快速诊断检测。在非使用者中,社区层面双AI长效驱虫蚊帐使用率>40%与预防疟疾感染显著相关:虫螨腈组(比值比:0.44(95%置信区间:0.27 - 0.71),p = 0.0009)、PBO组(比值比:0.55(95%置信区间:0.33 - 0.94),p = 0.0277)和吡丙醚组(比值比:0.61(95%置信区间:0.37 - 0.99),p = 0.0470),与仅含拟除虫菊酯长效驱虫蚊帐使用率>40%的群组中的非使用者相比。当社区层面使用率≤40%时,与仅含拟除虫菊酯长效驱虫蚊帐使用率>40%的群组中的非使用者相比,虫螨腈组对非使用者有一些预防疟疾感染的迹象(比值比:0.65(95%置信区间:0.42 - 1.01),p = 0.0528)。
我们的研究表明,当社区双AI长效驱虫蚊帐使用率达到40%或更高时,非使用者会从这些蚊帐的存在中受益。值得注意的是,即使在虫螨腈组中使用率≤40%,非使用者也比仅含拟除虫菊酯且覆盖率更高的组中的非使用者得到了更好的保护。使用者和非使用者之间观察到的疟疾风险差异更大,这表明长效驱虫蚊帐在为使用蚊帐的人提供个人预防疟疾感染保护方面发挥着关键作用。